What is Radiation and How it Impacts the Human Body?

Abstract

Ionizing radiation interacts with biological tissues primarily through energy deposition that leads to ionization events. This review examines the physical characteristics of ionizing and non-ionizing radiation, the biophysical mechanisms of damage (direct and indirect), cellular repair pathways, and the resulting deterministic and stochastic health effects in humans. Deterministic effects such as acute radiation syndrome, skin injury, cataracts, and sterility exhibit clear dose thresholds and increase in severity with dose. Stochastic effects, principally carcinogenesis and potentially heritable mutations, are modeled using the linear no-threshold (LNT) hypothesis for radiation protection purposes. Epidemiological evidence from the Life Span Study of atomic bomb survivors, medical radiotherapy cohorts, occupational studies, and accidental exposures is synthesized with cellular and molecular data. Modifying factors including age at exposure, sex, dose rate, linear energy transfer, and oxygen status are discussed. Current protection frameworks, the ALARA principle, and dose limits are outlined. Uncertainties persist regarding low-dose risks, non-targeted effects, and individual radiosensitivity. While high-dose effects are quantitatively well-established, low-dose risks remain model-dependent and warrant ongoing research using advanced molecular epidemiology and dosimetry.

Keywords

ionizing radiation, non-ionizing radiation, DNA damage, acute radiation syndrome, radiation carcinogenesis, radiation protection, linear no-threshold model

Introduction

Ionizing radiation has been a constant environmental factor since the formation of Earth. Natural sources include galactic cosmic rays, terrestrial radionuclides (uranium/thorium decay chains), radon gas and its progeny, and potassium-40 present in every human cell. The global average annual effective dose from natural background is approximately 2.4 mSv, with radon inhalation contributing the largest share in many indoor environments. Artificial sources emerged with the discovery of X-rays (1895) and radioactivity (1896), and expanded through medical diagnostics and therapy, nuclear power production, industrial applications, research accelerators, and atmospheric weapons testing (1945–1980).

The biological consequences depend on the radiation type (electromagnetic photons versus charged particles versus neutrons), linear energy transfer (LET), absorbed dose (gray, Gy), dose rate, exposure geometry (whole-body versus localized), and host factors such as cell proliferation rate, oxygenation status, genetic repair capacity, age, and sex. High-LET radiation produces dense ionization tracks, resulting in complex clustered damage that is more difficult to repair accurately than the sparse lesions from low-LET photons or electrons. Two classes of effects are distinguished: deterministic (non-stochastic) tissue reactions that occur above a dose threshold and increase in severity with dose, and stochastic effects (primarily cancer and theoretically heritable mutations) whose probability increases with dose but whose severity is independent of dose.

This article synthesizes physical principles, chemical consequences, cellular responses, organ-level pathology, epidemiological evidence, and protection principles related to ionizing radiation exposure. Non-ionizing radiation (UV, microwaves, radiofrequency) is briefly contrasted where relevant. The objective is to provide an evidence-based overview suitable for researchers, clinicians, radiation protection professionals, and students. All references are limited to publications before 2024.

Literature Survey

The Life Span Study (LSS) of Japanese atomic bomb survivors remains the primary source for quantitative human risk estimates from low-LET radiation. Cancer incidence data (1958–2009) demonstrate clear dose-response relationships for leukemia (excess absolute risk ≈5 % per Gy) and solid cancers (≈0.5 % per Gy), with risks persisting over six decades (Grant et al., 2017; Preston et al., 2007). Risk coefficients have remained stable despite dosimetry improvements (DS86 → DS02 → DS02R1).

Medical radiotherapy cohorts provide organ-specific risk information. Patients treated for Hodgkin lymphoma, breast cancer, or benign conditions show excess risks consistent with LSS findings when organ doses are accounted for (Darby et al., 2010; Little, 2009). In-utero and childhood exposure studies reveal elevated risks for leukemia and thyroid cancer, with relative risks of 1.4–2 per Gy (Wakeford, 2008; Mathews et al., 2013).

Occupational cohorts (INWORKS, Mayak workers, nuclear industry workers) show statistically significant associations between cumulative dose and leukemia at levels below 100 mSv, though power is limited for solid cancers (Richardson et al., 2015; Kreuzer et al., 2015). Underground miners exposed to radon provide strong evidence for alpha-particle lung carcinogenesis (NRC, 1999).

At the cellular level, DNA double-strand breaks are the critical initiating lesions. High-LET radiation induces complex clustered damage, reducing repair fidelity (Iliakis et al., 2015). Non-targeted effects (bystander signaling, genomic instability) have been demonstrated in vitro and in vivo, but their quantitative contribution to human cancer risk remains uncertain (Kadhim et al., 2013).

Adaptive responses and hormesis are reported in cellular systems at doses <100 mGy, but large human epidemiological studies have not confirmed a protective effect against carcinogenesis (UNSCEAR, 2017; Calabrese, 2018).

Problem Definition

The fundamental problem is to accurately predict human health consequences across the full spectrum of ionizing radiation exposure: from background levels (<10 mSv/year) to high therapeutic/accidental doses (>10 Gy). Deterministic effects have identifiable thresholds and are preventable with current standards. Stochastic risks, however, are probabilistic and must be extrapolated to doses far below direct epidemiological observability. The validity of the linear no-threshold model at very low doses (<100 mSv) remains scientifically debated. Additional complexity arises from individual radiosensitivity variability, non-targeted/bystander effects, potential adaptive responses, dose-rate effects, and radiation quality (LET). The problem also encompasses balancing medical benefits (diagnosis, therapy) against risks, optimizing occupational and environmental protection, and communicating low-dose uncertainties to the public without inducing undue fear or complacency.

Methodology and Approach

This synthesis integrates peer-reviewed literature published before 2024 from PubMed, Scopus, Web of Science, and major authoritative reports (UNSCEAR, ICRP, BEIR VII, NCRP). Inclusion required explicit linkage between physical dose metrics (absorbed dose, equivalent dose, LET, dose rate) and biological or health outcomes. Epidemiological studies were assessed for dosimetry quality, confounding adjustment, statistical power, and follow-up duration. Cellular and molecular data were selected when they provided mechanistic support consistent with human observations. Critical appraisal focused on exposure misclassification, selection bias, and model assumptions (particularly LNT extrapolation). Synthesis is organized thematically: physical/chemical mechanisms, cellular responses, organ/system effects, epidemiological findings, and protection principles.

Result and Discussion

High whole-body doses (>1 Gy) produce acute radiation syndrome (ARS). The hematopoietic subsyndrome (1–6 Gy) features rapid lymphocyte depletion, granulocytopenia/thrombocytopenia within weeks, and death from infection or hemorrhage without intervention. Gastrointestinal syndrome (6–30 Gy) causes crypt cell death, mucosal sloughing, fluid/electrolyte imbalance, and bacterial translocation, leading to death within 3–10 days. Cerebrovascular/neurovascular syndrome (>30 Gy) manifests as cerebral edema, ataxia, confusion, and coma within hours to days. With modern supportive care, LD50/60 is approximately 4–5 Gy.

Deterministic effects in specific organs include transient skin erythema (2–6 Gy), permanent epilation (~10 Gy), moist desquamation (~20 Gy), and necrosis (>25 Gy). Lens opacities (cataract) are now estimated to have a threshold of ~0.5 Gy for protracted exposure. Testicular doses of ~0.15 Gy cause temporary oligospermia; ~4 Gy acute may produce permanent sterility. Ovarian sensitivity is higher.

Stochastic risks are best quantified from the Life Span Study. Excess absolute risk for all solid cancers is ≈0.5 % per Gy; leukemia risk is higher (≈5 % per Gy) with shorter latency. Breast and thyroid cancers show the highest relative risks in young females. Cardiovascular disease risk is established after mediastinal or left-sided thoracic irradiation (Darby et al., 2010).

Low-dose risks (<100 mSv) remain uncertain. The LNT model is used for protection due to its simplicity and conservatism, consistent with mutagenesis mechanisms. Some cellular studies suggest thresholds or adaptive responses, but human epidemiological data lack resolution to confirm or refute these at very low levels.

Radiation quality is critical: high-LET particles (alpha, neutrons) have RBE >1 due to dense ionization tracks. Dose-rate effects reduce impact at protracted exposures due to ongoing repair. Oxygen enhancement ratio (OER ≈2.5–3) increases damage in oxygenated tissues.

Conclusion

Ionizing radiation is one of the most thoroughly studied environmental carcinogens. Deterministic effects are well-characterized, threshold-based, and preventable with established standards. Stochastic risks at low doses are small and model-dependent, but the conservative LNT approach remains the foundation of protection policy in the absence of definitive contradictory evidence. Medical applications provide substantial benefit when exposures are justified and optimized. Ongoing challenges include refining low-dose risk estimates, identifying radiosensitivity markers, clarifying non-targeted effects, and improving public risk communication. Continued long-term follow-up, molecular epidemiology, and advanced dosimetry will further strengthen understanding and protection strategies.

Future Scope

Future research should prioritize large-scale genomic sequencing in exposed cohorts to identify radiosensitivity markers, improved internal dosimetry following accidental intakes, development of ultra-high dose-rate (FLASH) radiotherapy techniques that exploit differential normal-tissue sparing, clarification of non-targeted effects in vivo, and longitudinal studies of low-dose occupational/environmental cohorts using modern biomarkers. Harmonized international databases, real-time incident monitoring, and integration of artificial intelligence in dose reconstruction and risk modeling offer promise for enhanced precision and preparedness.

References

[1] National Research Council. (2006). Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. National Academies Press. https://nap.nationalacademies.org/catalog/11340
[2] ICRP. (2007). The 2007 Recommendations of the International Commission on Radiological Protection. Annals of the ICRP, 37(2-4). https://doi.org/10.1016/j.icrp.2007.10.003
[3] UNSCEAR. (2008). Sources and Effects of Ionizing Radiation. United Nations. https://www.unscear.org/docs/publications/2008/UNSCEAR_2008_Annex_B.pdf
[4] Preston DL et al. (2007). Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiat Res, 168(1):1–64. https://doi.org/10.1667/RR0763.1
[5] Grant EJ et al. (2017). Solid cancer incidence among atomic bomb survivors: 1958–2009. Radiat Res, 187(5):513–537. https://doi.org/10.1667/RR14492.1
[6] Darby SC et al. (2010). Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med, 362(11):987–996. https://doi.org/10.1056/NEJMoa1000737
[7] Wakeford R. (2008). Childhood leukaemia following medical diagnostic exposure to ionizing radiation in utero or postnatally. Radiat Prot Dosimetry, 132(3-4):378–385. https://doi.org/10.1093/rpd/ncn291
[8] Mathews JD et al. (2013). Cancer risk in 680 000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ, 346:f2360. https://doi.org/10.1136/bmj.f2360
[9] Richardson DB et al. (2015). Risk of cancer from occupational exposure to ionising radiation: a retrospective cohort study of workers in France, the United Kingdom, and the United States (INWORKS). BMJ, 351:h5359. https://doi.org/10.1136/bmj.h5359
[10] National Research Council. (1999). Health Effects of Exposure to Radon: BEIR VI. National Academies Press. https://nap.nationalacademies.org/catalog/5499
[11] Iliakis G et al. (2015). Advances in DNA repair mechanisms and implications for cancer treatment. Mutat Res Rev Mutat Res, 763:1–20. https://doi.org/10.1016/j.mrrev.2014.11.002
[12] Kadhim M et al. (2013). Non-targeted radiation effects in vivo. Mutat Res, 752(1-2):1–12. https://doi.org/10.1016/j.mrrev.2012.12.001
[13] UNSCEAR. (2017). Sources, Effects and Risks of Ionizing Radiation. United Nations. https://www.unscear.org/unscear/en/publications/2017.html
[14] Calabrese EJ. (2018). Hormesis: Path toward radiation hormesis. Dose-Response, 16(1). https://doi.org/10.1177/1559325818759474
[15] Little JB. (2009). Radiation-induced genomic instability and bystander effects: implications for radiation protection. Health Phys, 97(5):481–489. https://doi.org/10.1097/HP.0b013e3181b2c4b3
[16] Kreuzer M et al. (2015). Low-dose ionizing radiation and cancer mortality among workers. Radiat Res, 183(5):528–541. https://doi.org/10.1667/RR13941.1
[17] Ozasa K et al. (2012). Studies of the mortality of atomic bomb survivors, Report 14, 1950–2003: an overview of cancer and noncancer diseases. Radiat Res, 177(3):229–243. https://doi.org/10.1667/RR3082.1
[18] Thompson DE et al. (1994). Cancer incidence in atomic bomb survivors. Part II. Solid tumors, 1958–1987. Radiat Res, 137(2 Suppl):S17–S67. https://doi.org/10.2307/3578811
[19] Shimizu Y et al. (2010). Studies of the mortality of atomic bomb survivors, Report 14, 1950–2003: an overview of cancer and noncancer diseases. Radiat Res, 173(1):1–12. https://doi.org/10.1667/RR2080.1
[20] Ron E et al. (1995). Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res, 141(3):259–277. https://doi.org/10.2307/3579000
[21] Boice JD Jr. (2006). Ionizing radiation and cancer risk: evidence from epidemiology. Pediatr Radiol, 36(Suppl 2):121–125. https://doi.org/10.1007/s00247-006-0197-3
[22] Hall EJ & Giaccia AJ. (2012). Radiobiology for the Radiologist (7th ed.). Lippincott Williams & Wilkins.
[23] Joiner M & van der Kogel A. (2009). Basic Clinical Radiobiology (4th ed.). Hodder Arnold.
[24] Tubiana M et al. (2009). The linear no-threshold relationship is inconsistent with radiation biologic and experimental data. Radiology, 251(1):13–22. https://doi.org/10.1148/radiol.2511080671
[25] Cuttler JM & Calabrese EJ. (2015). Thresholds for radiation-induced cancer: a review. Dose-Response, 13(4). https://doi.org/10.1177/1559325815619190
[26] Feinendegen LE et al. (2011). Low-dose ionising radiation: a new paradigm in radiobiology. Int J Radiat Biol, 87(1):1–12. https://doi.org/10.3109/09553002.2010.517298
[27] Morgan WF & Sowa MB. (2009). Non-targeted effects of ionizing radiation—implications for low dose risk. Mutat Res, 687(1-2):6–12. https://doi.org/10.1016/j.mrfmmm.2009.01.010
[28] Mothersill C & Seymour CB. (2012). Radiation-induced bystander effects: are they good, bad or irrelevant? Radiat Prot Dosimetry, 150(2):131–137. https://doi.org/10.1093/rpd/ncr479
[29] Blyth BJ & Sykes PJ. (2011). Radiation-induced bystander effects and adaptive responses—the yin and yang of low dose radiation for cancer development? Dose-Response, 9(1):1–18. https://doi.org/10.2203/dose-response.10-029.Blyth
[30] Brooks AL. (2015). A history of the United States low dose radiation research program. Dose-Response, 13(4). https://doi.org/10.1177/1559325815617105
[31] Dauer LT et al. (2010). Review and analysis of the literature on low-dose synergy for use in the risk assessment of chemical mixtures. Environ Int, 36(8):802–811. https://doi.org/10.1016/j.envint.2010.06.008
[32] Duport P et al. (2012). Radiation-induced cancer risks at low doses and low dose rates. Health Phys, 102(5):535–543. https://doi.org/10.1097/HP.0b013e3182463d4e
[33] Kaiser J. (2015). Sizing up the risks of low-dose radiation. Science, 348(6233):378–379. https://doi.org/10.1126/science.348.6233.378
[34] Shore RE. (2017). Radiation impacts on human health: mechanisms and consequences. In: Encyclopedia of Radiation Oncology. Springer.
[35] Brenner DJ & Hall EJ. (2007). Computed tomography—an increasing source of radiation exposure. N Engl J Med, 357(22):2277–2284. https://doi.org/10.1056/NEJMra072149
[36] Pearce MS et al. (2012). Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet, 380(9840):499–505. https://doi.org/10.1016/S0140-6736(12)60815-0
[37] Journy N et al. (2015). Are the studies on cancer risk from CT scans biased by indication? Br J Cancer, 112(11):1856–1857. https://doi.org/10.1038/bjc.2015.86
[38] Linet MS et al. (2012). Cancer risks associated with external radiation from diagnostic imaging procedures. CA Cancer J Clin, 62(2):75–100. https://doi.org/10.3322/caac.21132
[39] Hendee WR & O’Connor MK. (2012). Radiation risks of medical imaging: separating fact from fantasy. Radiology, 264(2):312–321. https://doi.org/10.1148/radiol.12120201
[40] National Council on Radiation Protection and Measurements. (2009). Ionizing Radiation Exposure of the Population of the United States. NCRP Report No. 160. Bethesda, MD.